Sidley represented Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage biotechnology company developing next-generation therapeutics for difficult-to-treat cancers, in its underwritten public offering of common stock, pre-funded warrants, and accompanying common warrants. The offering is expected to generate approximately US$110 million in gross proceeds, with the potential for up to approximately US$172.6 million in additional gross proceeds if the warrants are exercised in full.
The Sidley team was led by Asher Rubin (Technology and Life Sciences Transactions) and Istvan Hajdu (Capital Markets), and included Henry Dickinson and Eric Carlson (Capital Markets); Torrey Cope and Lauren Limbach (Food, Drug and Medical Device); and Dan Altman and Ryan Kelly (Tax).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
